Novel azapeptide inhibitors of hepatitis c virus serine protease

被引:31
|
作者
Bailey, MD [1 ]
Halmos, T [1 ]
Goudreau, N [1 ]
Lescop, E [1 ]
Llinàs-Brunet, M [1 ]
机构
[1] Boehringer Ingelheim Canada Ltd Res & Dev, Laval, PQ H7S 2G5, Canada
关键词
D O I
10.1021/jm049864b
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Azapeptides are known inhibitors of several serine and cysteine proteases. In seeking different classes of inhibitors for the HCV serine protease, a series of novel azapeptide-based inhibitors were investigated which incorporated noncleavable P1/P1' aza-amino acyl residues. Extensive SAR studies around the P1/P1' aza-amino acyl fragment resulted in the identification of potent and selective inhibitors. Using NMR studies, we have shown that this series of inhibitors bind in a noncovalent competitive fashion to the NS3 protease active site. The bound conformation of one of these new azapeptide-based inhibitors was determined using the transfer NOE technique. Incorporation of these new aza-amino acyl functionalities in the P1 position provided a handle to probe for new interactions in the S' region of the enzyme.
引用
收藏
页码:3788 / 3799
页数:12
相关论文
共 50 条
  • [31] Hepatitis C virus serine protease: synthesis of radioactive and stable isotope-labeled potent inhibitors
    Latli, Bachir
    Hrapchak, Matt
    Gorys, Vida
    Llinas-Brunet, Montse
    Campbell, Scot S.
    Song, Jinhua
    Senanayake, Chris H.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2014, 57 (05): : 350 - 357
  • [32] Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease:: Towards smaller inhibitors
    Llinàs-Brunet, M
    Bailey, M
    Fazal, G
    Ghiro, E
    Gorys, V
    Goulet, S
    Halmos, T
    Maurice, R
    Poirier, M
    Poupart, MA
    Rancourt, J
    Thibeault, D
    Wernic, D
    Lamarre, D
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (20) : 2267 - 2270
  • [33] Peptidic inhibitors of the hepatitis C virus serine protease within non-structural protein 3
    Fischmann, TO
    Weber, PC
    CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (28) : 2533 - 2540
  • [34] Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles
    Chen, KX
    Njoroge, FG
    Arasappan, A
    Venkatraman, S
    Vibulbhan, B
    Yang, WY
    Parekh, TN
    Pichardo, J
    Prongay, A
    Cheng, KC
    Butkiewicz, N
    Yao, NH
    Madison, V
    Girijavallabhan, V
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (03) : 995 - 1005
  • [35] Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3 serine protease inhibitors
    Arasappan, Ashok
    Njoroge, F. George
    Parekh, Tejal N.
    Pichardo, John
    Butkiewicz, Nancy
    Prongay, Andrew
    Yao, Nanhua
    Girijavallabhan, Viyyoor
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2604 - U2604
  • [36] Novel, sulfonamide linked inhibitors of the hepatitis C virus NS3 protease
    Kirschberg, Thorsten A.
    Squires, Neil H.
    Yang, Huiling
    Corsa, Amoreena C.
    Tian, Yang
    Tirunagari, Neeraj
    Sheng, X. Christopher
    Kim, Choung U.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (03) : 969 - 972
  • [37] The Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase Inhibitors
    Kwo, Paul Y.
    Vinayek, Rakesh
    GUT AND LIVER, 2011, 5 (04) : 406 - 417
  • [38] A high throughput assay for identification of hepatitis C virus NS3 serine protease inhibitors.
    Zemel, R
    Berdichevsky, Y
    Bachmatove, L
    Kunin, M
    Golan-Goldhirsh, A
    Tur-Kaspa, R
    Benhar, I
    HEPATOLOGY, 2001, 34 (04) : 423A - 423A
  • [39] Prime site binding inhibitors of a serine protease:: NS3/4A of hepatitis C virus
    Ingallinella, P
    Fattori, D
    Altamura, S
    Steinkühler, C
    Koch, U
    Cicero, D
    Bazzo, R
    Cortese, R
    Bianchi, E
    Pessi, A
    BIOCHEMISTRY, 2002, 41 (17) : 5483 - 5492
  • [40] Recent developments in the discovery of hepatitis C virus serine protease inhibitors -: towards a new class of antiviral agents?
    Narjes, F
    Koch, U
    Steinkühler, C
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (02) : 153 - 163